Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00788710
Other study ID # 0663-097
Secondary ID 2008_578
Status Completed
Phase Phase 3
First received
Last updated
Start date October 2008
Est. completion date July 2010

Study information

Verified date February 2022
Source Organon and Co
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of etoricoxib compared to placebo in the treatment of postoperative pain associated with total abdominal hysterectomy.


Recruitment information / eligibility

Status Completed
Enrollment 430
Est. completion date July 2010
Est. primary completion date July 2010
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients 18 years or older in generally good health who are scheduled to have a total hysterectomy and who are willing to limit alcohol consumption Exclusion Criteria: - Patient is allergic to the study drug, other cyclooxygenase-2 (COX-2) inhibitors/nonsteroidal anti-inflammatory drugs (NSAIDS), ibuprofen, morphine, or oxycodone or has hypersensitivity to aspirin or other NSAIDS - Patient has uncontrolled high blood pressure - Patient has a history of drug and/or alcohol abuse within the last 5 years - Patient has taken part in another investigational study within 4 weeks of the start of study - Patient is breast-feeding - Patient has an active ulcer or inflammatory bowel disease

Study Design


Related Conditions & MeSH terms

  • Acute Pain
  • Acute Pain Following a Total Abdominal Hysterectomy

Intervention

Drug:
etoricoxib (MK0663) 120 mg
120 mg of etoricoxib (MK0663) for a total of 5 days
Comparator: Placebo
Placebo tablets once daily on Days 1-5. Total treatment is 5 days.
etoricoxib (MK0663) 90 mg
90 mg of etoricoxib (MK0663) for a total of 5 days

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Organon and Co

Outcome

Type Measure Description Time frame Safety issue
Primary Average Pain Intensity at Rest Over Days 1 to 3 Pain intensity at rest was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine. 3 Days
Secondary Average Total Daily Dose of Morphine Over Days 1 to 3 3 days
Secondary Average Elicited Pain Upon Sitting Over Days 1 to 3 Elicited pain upon sitting was measured on a 0- to 10-point scale: 0=no pain, to 10=pain as bad as you can imagine. 3 days